OrbiMed’s Global Blood Therapeutics, Inc. GBT Stock Holding History

OrbiMed’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,000	Closed	-$1.73M	–	158
2022 Q1	$1.73M	Buy	+50,000	New	+$1.49M	0.03%	135

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OrbiMed's GBT Position: Q3 2022 in Review

OrbiMed sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 2,044,000 shares — an estimated $65.3K sold.

OrbiMed first reported a position in GBT in Q1 2017 and held it in 9 quarters. The position peaked at $84.9M in Q4 2017. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

OrbiMed reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
OrbiMed sold 2,044,000 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $65.3K.
OrbiMed first reported a position in Global Blood Therapeutics, Inc. in Q1 2017 and held it in 9 quarters.
OrbiMed's Global Blood Therapeutics, Inc. position peaked at $84.9M in Q4 2017.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.